Olutasidenib
Cohort 1a and 1b: Glioma (Advanced Gliomas and Glioblastoma Multiforme)
Rigel PharmaceuticalsSmall moleculePhase 4 / ApprovedActive
BBB
72/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 57/ 100
- Competitive Position
- 95/ 100
Competitive context
95 Active assets in the Cohort 1a and 1b: Glioma (Advanced Gliomas and Glioblastoma Multiforme) cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Irinotecan Kailin Yang, MD, PhD | Phase 3 | B |
Valproic Acid Medical University of South Carolina | Phase 2 | B |
DIANHYDROGALACTITOL Kintara Therapeutics, Inc. | Phase 2 | B |
Cyclophosphamide Essen Biotech | Phase 2 | B |
CARMUSTINE University of California, Davis | Phase 3 | B |
View all 50 →
Same molecule, other indications
Olutasidenib is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →